Clinical Trials in Mesothelioma

$290,979P01FY2013CANIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 34663807 Paper 33341086 Paper 32069268 Paper 31420241 Paper 29550074 Paper 29508763 Paper 29399394 Paper 28862644 Paper 27258611 Paper 27045023 Paper 26979791 Paper 26973126 Paper 26968202 Paper 26330166 Paper 26324743 Paper 25979873 Paper 25941351 Paper 25600436 Paper 25104548 Paper 24919573 Paper 24778279 Paper 24719232 Paper 24579088 Paper 24439255 Paper 24329786 Paper 24274181 Paper 24018559 Paper 23883116 Paper 23865808 Paper 23576561 Paper 23486267 Paper 23481185 Paper 23481183 Paper 23411061 Paper 22742411 Paper 22348096 Paper 22054892 Paper 22008913 Paper 21838572 Paper 21819972 Paper 21642245 Paper 21610146 Paper 21148741 Paper 20980695 Paper 20926399 Paper 20700700 Paper 20683443 Paper 20118240 Paper 20068553 Paper 20028856 Paper 20016540 Paper 19859065 Paper 19773437 Paper 19732719 Paper 19715403 Paper 19211796 Paper 19074893 Paper 18841331 Paper 18559619 Paper 18463540 Paper 17671130 Paper 17638914 Paper 17617589 Paper 17582217 Paper 17332368 Paper 17080181 Paper 16488193 Paper 16397045 Paper 16357188 Paper 16325129 Paper 16243818 Paper 16166452 Paper 16166316 Paper 15846066 Paper 15622005 Paper 14633712 Paper 11916486 Paper 11578910 Paper 11228529 Paper 11202452 Paper 11020355 Paper 10955822 Paper 10770637 Paper 10694702 Trial NCT01212367 Trial NCT00299962 Patent 9994818 Patent 9937205 Patent 9365641 Patent 9133436 Patent 7238526 Patent 6475769 Patent 6428968 Patent 12128069 Patent 11931380 Patent 11718685 Patent 11274298 Patent 11001805 Patent 10421960 Patent 10329355

Abstract

The overall hypothesis of this project is that immuno-gene therapy can be used successfully to treat malignant pleural mesothelioma (MPM). The Project will continue to move the preclinical findings from Projects 2 and 3 into cutting-edge clinical trials (bench-to-bedside); and to provide clinical data and specimens back to Projects 2 and 3 to inform improvements in the next iteration of clinical trials (bedside-to bench). The first focus of this project is to continue and extend successful trials using intrapleural injections of an adenovirus (Ad) expressing type 1 interferon (Ad.lFN). Based on preclinical data from Project 2, a Phase 1/2 trial was initiated combining two Ad.IFN-alpha doses (given 3 days apart) with concomitant Celecoxib administration, followed two weeks later by 4-6 cycles of either front-line (pemetrexed/cisplatin/) or second-line (gemcitabine/carboplatin) chemotherapy. Aim 1 of this proposal is to complete the Phase 2 trial to determine if the response rate warrants moving this therapy to a larger randomized Phase 2 or 3 trial by either industry or cooperative groups. The second focus of the Project is adoptive T cell therapy using T cells with chimeric antigen receptors (CARs) initially targeted to the mesothelioma tumor surface antigen, mesothelin. Given potential safety concerns with some other CARs, a trial using T-cells transduced with GMP grade mRNA will be conducted (Aim 2A). Since CAR expression time is limited, if any

View original record on NIH RePORTER →